3 results about "Antiepileptic Agents" patented technology

A genetically-modified rat having a PKHD1L1 gene with a point or other mutation and a construction method thereof are disclosed. A CRISPR / Cas9 system knocks the PKHD1L1 gene into a rat source, and a codon changes from TTA to TCA to construct the mutant PKHD1L1 gene. The genetically-modified rat can be applied to epilepsy pathogenesis studies and design and testing of new anti-epileptic drugs. Methods for detecting abnormal cortical excitability and detecting an epileptic phenotype of an animal can use the genetically-modified rat. A somatosensory evoked potential is used to detect whether the genetically-modified rat has an abnormal cortical excitability phenotype, so as to confirm whether the rat can be a successful model for testing anti-epileptic drugs. The method can detect abnormal cortical excitability and verify the effectiveness of anti-epileptic drugs or treatments.

This invention discloses a glutamate-responsive nanoliposome, its preparation method, and its application in antiepileptic treatment. The glutamate-responsive nanoliposome comprises liposomes, glutamate oxidase, DSPE-TK-mPEG, and an antiepileptic drug. The glutamate oxidase is encapsulated in the hydrophilic region at the center of the liposome, the antiepileptic drug is loaded in the hydrophobic region of the liposome bilayer, and DSPE-TK-mPEG is modified onto the liposome bilayer membrane. The preparation method includes: first preparing a lipid solution, adding an antiepileptic drug solution and glutamate oxidase, and obtaining drug-loaded nanoliposomes through repeated extrusion. The glutamate-responsive drug-releasing nanoliposomes of this invention can significantly improve the stability and bioavailability of antiepileptic drugs, overcoming the shortcomings of traditional antiepileptic drugs in the treatment process. By optimizing the preparation of liposomes, a good drug delivery platform for antiepileptic drugs is provided.

This application relates to the field of analytical detection technology, specifically to sample pretreatment methods, kits, and detection methods for the detection of antiepileptic drugs. The sample pretreatment method for the detection of antiepileptic drugs in this application includes one or more of the following antiepileptic drugs: valproic acid, carbamazepine, phenytoin, levetiracetam, lamotrigine, and phenobarbital. The sample pretreatment method includes the following steps: mixing magnetic beads with an activation solution to prepare a magnetic bead suspension; mixing the sample to be tested, the magnetic bead suspension, and an internal standard solution, and separating the supernatant and the magnetic bead complex after magnetic adsorption treatment; adding an eluent to the magnetic bead complex, and collecting the magnetic bead-target complex after elution treatment; adding an elution buffer to the magnetic bead-target complex, and collecting the supernatant after elution treatment for detection. The above sample pretreatment method is simple to operate, time-saving, and low-cost, providing key technical support for the efficient quantitative detection of antiepileptic drugs.